Table of Contents
What is GcMAF?
Gcmaf is a vitamin D-binding protein. It’s scientifically referred to as Gc protein-derived macrophage activating aspect. It’s a protein that supports the immune system, and naturally found in the body. Gcmaf triggers macrophage cells, or the cells responsible for fighting off infection and illness. (1 )
The two latest publications on gcmaf help reinterpreting the biological and medical results individually observed in vitro and in vivo by a variety of scientists. The hypothesis that chondroitin sulfate might be accountable for the results thus far credited to gcmaf, solves al the inconsistencies and contradictions that have identified this field of immunotherapy. Furthermore, this hypothesis lays the foundation for the advancement of non-proteinic macrophage activating aspects that are not extracted from human blood, therefore avoiding all the risks related to human blood-derived products. (2 ).
GcMAF Research study
A 1997 research study checked gcmaf on mice with cancer. It found that gcmaf improved their survival from 16 days to 32 days.
A few years later on, the researchers evaluated the treatment on people with breast, colorectal, and prostate cancers. They provided shots of a small quantity of gcmaf once a week. After a few months, all of the patients were cured, according to the studies. Four to 7 years later on, their cancers had not return.
These results sound remarkable, however there were some huge problems with the research studies. For one thing, they were really little– simply 8 to 16 people each. Everyone in the studies had already been on basic cancer treatments like surgical treatment, chemotherapy, or radiation. So it was hard to inform whether these treatments, or gcmaf, triggered the cancers to shrink.
Likewise, medical professionals usually utilize imaging and laboratory tests to stage cancers– to put it simply, to see how big the cancer is and whether it has spread out. The researchers didn’t do this. Instead, they took blood tests to inspect nagalase levels, which isn’t a tested way to check for cancer or to see if it has gotten smaller.
Lastly, the researchers never evaluated whether gcmaf actually activated macrophages in the patients’ blood. So they could not make certain that the treatment was working at all.
3 physicians from the Anticancer Fund, a not-for-profit group that promotes cancer research study, published a letter in 2014 that described much of the interest in the research studies. They found numerous errors in the research studies’ claims and stated that its conclusions “make no sense.”.
Future of gcmaf
A few researchers are still investigating gcmaf as a possible cancer treatment. Some early studies recommend that it may be handy for individuals with late-stage cancers. It’s difficult to know whether gcmaf works. The studies that have been done so far took a look at very small numbers of individuals. Some of them included only one individual. Larger research studies are needed to prove that this treatment works on cancer which it’s safe.
Macrophages might still hold guarantee. Researchers are trying to discover whether monoclonal antibodies or other drugs might help macrophages kill cancer cells.
Till we know more, medical professionals stay with other immunotherapies, like checkpoint inhibitors, that have more evidence behind them. If you have questions about gcmaf or any other cancer treatment you’ve read about online, your cancer medical professional is the best individual to address them. (3 ).
Illness for GcMAF Therapy
GcMAF macrophage activation treatment works in the treatment of many illness, such as cancer, HIV AIDS, Hepatitis B virus (HBV), Liver disease C virus (HCV), Herpes Simplex infection (HSV), Tuberculosis, Pneumonia infection, Epstein-Barr virus (EBV), cystitis/urinary system infection (UTI), Endometriosis, Selective iga deficiency disorder and influenza virus.
In healthy individuals the immune system might have the ability to get rid of many kinds of illness, nevertheless individuals with a jeopardized body immune system will take advantage of gcmaf treatment.
In the excellent bulk of individuals there are no side-effects with our 2nd generation GcMAF treatment, or side-effects are extremely minor and exceptionally rare. Low grade fever and eczema has actually been observed in about 1 out of 100 patients utilizing gcmaf however these were short-term impacts.
Treatment in our clinic has been by Intramuscular (IM), Subcutaneous (SC) and Intramural (IT) injection.
In Mix With Other Treatments gcmaf can be safely used with a variety of other basic treatments and drugs to improve their impact. We refer to this as integrative medication.
A mix with anti-cancer drugs and radiation therapy (radiotherapy) is possible. For maximum result and gain from gcmaf, administer a few days apart from chemotherapy. Radiation therapy does not have substantial effects on GcMAF, so both can be used together at any time. In our clinical experience we have actually observed considerable cancer killing effects from gcmaf integrated with palliative radiotherapy in patients who went through significant prior chemotherapy treatment.
Studies reveal that gcmaf has anti-angiogenic activity in addition to growth killing activity through the activation of macrophages.
Gcmaf can be integrated with Sonodynamic Therapy (SDT), Photodynamic Treatment (PDT) or both (Sonophotodynamic Treatment, SPDT), Maitake Extract, Coley Vaccine (Coley Fluid), high-dose IV Vitamin C, low dose Naltrexone (LDN), Alpha-Lipoic Acid, hyperthermia treatment, immunotherapies and cancer vaccines (such as autologous cancer vaccine).
Gcmaf needs to be used in mix with at least 5,000 IU vitamin D3 daily. Blood levels of vitamin D are often low in numerous illness such as cancer, HIV AIDS, etc. Regular vitamin D levels are needed for gcmaf to work totally. Have your blood 25 hydroxy-vitamin D and calcium levels evaluated. If blood calcium levels end up being elevated, vitamin D3 dosages may require to be minimized to accomplish an optimal balance.
Mixes to Avoid GcMAF can be safely used with a variety of drugs and other treatments. However, we recommend:.
Very little use of steroids is preferable because of their immune suppressing result, nevertheless steroids may be securely utilized with gcmaf if essential and recommended by your doctor.
Radiation treatment is chosen over chemotherapy whenever possible.
Treatment is by intramuscular (IM) or subcutaneous (SC) injection of the gcmaf macrophage triggering factor, 1-2 times per week (or as recommended by the treating doctor).
Treatment in our center has also been by intramural (IT) injection although IM and SC injections are by far the most common technique of administration.
Great aseptic handling with ethanol is required when using the vials. (4 ).
How does GcMAF work?
Gcmaf is a glycoprotein that triggers macrophages which in turn increases macrophage activity and changes them into Natural Killer (NK) cells.
Gcmaf has actually been clinically shown to be largely without any major adverse effects. Just flu-like symptoms in couple of portion of those who receive the injection. (5 ).
To be more particular:
In a healthy individual macrophages in our blood stream scour our bodies and kill malignancies; they get the message to go on the attack from Gc MAF, which is converted from Gc Protein. However malignant cells like cancer send out an enzyme called Nagalase that stops conversion of Gc protein to Gc MAF (Macrophage Activating Aspect); so the macrophages never get the message to enter into action in this way cancer suppresses the immune system, and cancer cells grow uncontrolled.
To reverse this we extract Gc Protein from blood; customize it outside the body to become the missing out on GcMAF, and inject it once a week for 25 weeks for early cancers, 50 or more weeks for late stage cancers. (Encapsulated tumours require extra treatment.) HIV can need just 16 weeks.
In its role of immune system regulator, gcmaf reverses other illness that assault the immune system like Osteoporosis, Aids, Hodgkins, Lupus, MS, Fibromyalgia, Parkinsons, numerous bacterial and viral infections and various types of Immune dysfunction.
Little pre-clinical trials to construct the case are again happening.
Those detected with any of these health problems or who are otherwise encouraged of the benefits of gcmaf for their health and who have actually done their own research on it are invited to respond. We request a copy of diagnostic details and upgrade reports from a doctor during and after treatments, to assist develop the case that gcmaf is a cure for numerous illnesses, which will assist to make it offered to the public. Individuals are complimentary to stop at any time. (6 ).
An extremely relevant GcMAF history
Gcmaf initially sprang to internet prestige in 2015, with an alternate health and conspiracy publication, Natural News, declaring the following.
A particular cure called gcmaf (short for “Gc protein-derived macrophage activating aspect,” which is a chemically modified kind of a natural protein that presumably promotes the activity of a specific sort of white blood cell) “has the prospective to be a universal treatment for cancer”.
It didn’t take long for gcmaf to obtain messianic status on the planet of online hocus pocus and make-believe medical treatments. Natural News continued in the very same post;
” [gcmaf] is also thought,” the website reported, “to be efficient in treating and reversing autism, HIV, liver/kidney illness and diabetes.” Report has it that gcmaf has the possible to be a remedy for a lot more illness, such as herpes, as well.”.
In spite of the various research short articles published in credible medical journals (most now withdrawed) declaring to verify gcmaf as reliable in the treatment of cancers, gcmaf does not treat cancer, or for that matter, any other disorder. It was, and possibly still is, a drug for which there is no clear scientific proof to suggest efficacy for anything. Hints of pledge have never equated into real results.
How it happened thought about by some as the cure-all for cancer, is another tale totally, and one well worth following. In a 2017 expose by Snopes, competently assisted by the Anticancer Fund (ACF), gcmaf was finally exposed. In the post, its creator and primary proponent, Dr. Nobuto Yamamoto. Was revealed to be guilty of falsifying clinical trials in a concerted decades-long effort to offer the lie of gcmaf.
The seriousness and ramifications of Yamamoto’s fraud have extensive implications for the medical neighborhood, its publications, and the processes it depends on to verify brand-new medications. It has highlighted how a once-respected member of the medical community can go rogue, using the system’s “fail-safes” versus it. The gcmaf legend shouldn’t be forgotten. It serves as a long-term suggestion of unaddressed industry loopholes, the majority of which stay in place.
The outcome of publishers not eliminating flawed research leads to yet more documents, based upon the theories promoted in the initial disproven research study. Here is a classic example, where 2 of Yamamoto’s papers on gcmaf have actually been referenced by scientists, in a current paper entitled “Prospective function of gcmaf in suppressing the seriousness of COVID-19-induced immune reactions: Lesson gained from HIV”.
Two concerns to the publications included. Why have you declined to retract Yamamoto’s incorrect documents and where is the peer evaluation procedure that would determine the research in the paper referenced above to be flawed? Allowing incorrect and problematic studies to continue threatens the public.
You can find the total Snopes Post here. Entitled, “How a Retired Researcher’s Questionable ‘Institute’ Convinced the Internet That Cancer Was Treated”, it makes for interesting reading and we advise it as a case study in expertly perpetrated pharmaceutical deceptiveness. Yamamoto had enjoyed a long and distinguished profession till gcmaf, making the motivation for the fraud that much harder to determine, and specialists stay divided on his real motivation.
In November of 2009, Yamamoto successfully offered his patents for gcmaf and associated copyright to an Israeli biopharmaceutical company, Efranat Macrophage. The business, after at first embracing Yamamoto, gradually distanced itself from him, rebranding gcmaf as EFF-022 and reaching changing the drug’s name mid-trial.
While the medical neighborhood gradually turned their backs on gcmaf, the alternate health and conspiracy areas of the internet were far from made with their new darling, having seen the marketing and sales potential for this brand-new “miracle” cure. (7 )
” Cancer cured for good?”– GcMAF and the miracle remedy
As an organisation devoted to beating cancer, we have a deep-rooted interest in any new research study advancements that could lead to brand-new, more effective treatments for the illness.
So when we got an enquiry from an advocate about an article entitled “Cancer cured for good” by Bill Sardi and Timothy Hubbell * we were captivated. The post discuss research by Nobuto Yamamoto in the United States, taking a look at a protein called GcMAF (aka gcmaf). His published research studies appear to reveal that injections of very percentages of GcMAF can “cure” people with breast, bowel and prostate cancer.
According to the post, “It works 100% of the time to get rid of cancer totally, and cancer does not recur even years later on.” Could this be the so-called ‘cure for cancer’ that we’ve been looking for all these years?
Sadly– just like numerous things in life– if it sounds too excellent to be real it most likely is. Major questions are now being raised about GcMAF (for instance, this examination by the BBC) and the business that offer it, and it is not licensed in the UK to deal with any illness.
Let’s explore a bit further.
What’s the idea behind it?
Dr Yamamoto studies the body immune system– the highly complex network of cells that helps to keep us healthy. The cells of the body immune system– leukocyte– fight bacterial and viral infections because they can recognise and assault these ‘foreign’ intruders. However they’re not so proficient at taking on cancer, considering that tumours grow from our own cells and have smart systems to ‘mask’ them from immune attack.
Macrophages (significance “huge eaters” in Greek) are a crucial type of white blood cell. They patrol the body, consuming foreign intruders and dead cells. They also help to inform other immune cells to the presence of infections.
Macrophages can be stirred into action by a small sugar-coated protein (glycoprotein) called GcMAF, short for Gc Macrophage Triggering Factor, which is produced by the body. But it’s thought that the production of GcMAF is blocked by an enzyme called Nagalase (alpha-N-acetylgalactosaminidase), produced by numerous cancers. This is one of the mechanisms that helps tumours evade the body immune system.
Yamamoto’s theory is that injecting cancer clients with GcMAF ought to trigger their macrophages to eliminate the cancer. He evaluated it back in 1997 in a paper released in the journal Cancer Research study, revealing that injecting GcMAF into mice transplanted with cancer cells might enhance their survival from around 16 days to around 35.
However the treatment did not ‘cure’ the cancer, as the cancer cells continued to increase, ultimately killing the animals.
Nevertheless, there are questions about the science underpinning the concept that GcMAF can treat cancer. For instance, other researchers have found no distinctions in the levels of GcMAF between cancer clients and healthy people– and the levels they do discover are far higher than the extremely small dosages proposed to work by Yamamoto. It’s difficult to see precisely how this finding fits with the concept of how the treatment is supposed to work, and it doesn’t support making use of GcMAF as a treatment for cancer.
Fast-forward a couple of years, to the publication of three documents detailing the outcomes of scientific trials of GcMAF performed by Yamamoto, evaluating the treatment on patients with breast, bowel and prostate cancer.
Note: The breast cancer paper has actually now been retracted, due to numerous worry about the work. Find out more on the retractionwatch blog site. The bowel cancer paper has actually also now been withdrawed. This letter details a few of the concerns about the work.
The outcomes seem stunning– all the clients on the trials are ‘cured’ of cancer. Certainly this is a remarkable breakthrough?
Put candidly, no it isn’t. There are significant clinical problems with the trials. For a start, all the studies are very small, including less than twenty clients in each– instead of the thousands needed to make the sort of claims discussed above.
Next, all the patients involved had gotten basic treatment for their cancer, consisting of surgery, chemotherapy and/or radiotherapy. This is a rather unconventional style for a trial of this kind, since it makes it very challenging to tell if any successes are due to the new drug, or the more conventional treatments.
On top of this, the researchers didn’t actually monitor the progress of tumours in the patients, and provide no medical details about them. Rather they decide to measure levels of Nagalase in the blood, rather than taking a look at any standard established markers for cancer.
For example, when it comes to the breast cancer patients, there is no information about their “TNM” (tumour, node, metastasis) status. This is a basic procedure of how far a client’s cancer has spread, and is utilized to compute the likelihood that it will return.
Additionally, the researchers didn’t do any tests to show that injected GcMAF was actually triggering macrophages in the patients’ blood, or perhaps operating in the manner in which they expect. There is no information about levels of cytokines– the proteins produced by immune cells when they are activated– or analysis of the patients’ immune cells.
Perhaps most considerably, there are no controls– unattended patients for comparison– and the studies only followed the patients for a couple of years. We have no other way of informing whether their cancers were growing again, or had actually been effectively treated, and whether this was because of GcMAF or the other treatment they had received.
Considered that 80 per cent of all females with breast cancer survive for at least 5 years, an uncontrolled study showing that 16 females of unidentified TNM status endure for at least 4 years is no great shakes, clinically speaking.
Another little study of 20 clients with a series of cancers, released in 2013, has similar issues. It’s not a controlled trial, and the scientists just determine nagalase levels as an indicator of whether the treatment is ‘working’, and supply extremely little difficult medical information (such as scans or other recognised tests) about the clients’ actual tumours. For example, in one concerning case, although the researchers showed that an ovarian cancer client’s nagalase levels had actually decreased, the levels of another marker– CA125, which is produced by ovarian cancer cells– had actually gone up. Yet this is classed as an “improvement” in the paper, without any other supporting info. Overall, this research study is likewise a long way from being persuading evidence that the treatment works.
Another informing point is the kind of journal in which the research study was published. If this research was truly groundbreaking, and pointed the way to a remedy for cancer, then the research would likely be discovered in top-tier ‘high-impact’ medical journals like The Lancet, The New England Journal of Medication or the Journal of the American Medical Association.
And lastly, practically all the recommendations in the documents are to other documents released by Yamamoto and his team. If GcMAF was certainly an appealing prospect for an effective cancer treatment, you ‘d anticipate plenty of other research study to reveal the very same thing. Researchers are usually quick to identify promising, emerging fields of research and jump on the bandwagon.
The poor quality of clinical papers supporting gcmaf is gone over here on the Scholarly Open Access blog.
Is there hope?
Although this particular approach isn’t all it’s hyped approximately be, harnessing the power of body immune system could be a really potent way to treat cancer.
And lots of Cancer Research UK-funded researchers are also working in this field. For instance, Teacher Fran Balkwill and her team are dealing with ways to trick macrophages and other immune cells into attacking cancer cells.
In 2014, scientists in Israel started a small early-stage clinical trial taking a look at the dose and security of gcmaf in cancer clients. (8 ).
Dr Yamamoto mentions gcmaf does not have side effects. Our experiences agree: gcmaf has actually revealed no side effects of its own. That’s not unexpected– your body anticipates to have it.
However your rebuilt body immune system might in many cases provide you minor negative effects, however bigger negative effects with late stages of cancer, and occasionally serious effects with autism, HIV and ME/CFS, as infections fight back against the rebuilt body immune system’s attack.
People’s responses to a reconstructed immune system are extremely various– from absolutely no, which is typical, to serious in a minority of cases.
Inside 2 hours gcmaf will start to impact your body immune system, and (if your immune system is at least partly active) a shot of 0.1 ml or more may trigger exhaustion which usually lasts 3-4 hours. You might feel much better than usual for the very first 2-3 weeks as the body immune system wakes up.
Gcmaf is a protein that your body ought to have made by itself, and there is a tiny opportunity (under 0.1%) you might have an allergy, generally within the very first 2 hours. If in doubt start with a 0.05 ml dosage, then 0.1 after 12 hours. If you do have a response, it can be treated with anti-histamine tablets, which can normally be purchased from a chemist without prescription (hay fever is an allergy).
We have actually seen positive, but not yet unfavorable autoimmune responses.
Other small side effects may include cytokine activity (with accompanying fatigue and minor weight loss, no such reports yet), histamine release (with potentially a headache) and the symptoms of a fever (3.5 hours of hot flushes) as the body immune system goes to work.
Many never observe anything more than an enhancing sense of well being. (9 ).
Other essential points
Activating macrophages with High Dosage GcMAF is an important part of any treatment program which can be utilized alone or in mix with a lot of other treatments.
GcMAF works especially well in synergy with targeted treatments which don’t damage the body immune system. Examples of targeted therapies include hormonal agent treatments, monoclonal antibody drugs, small-molecule drugs, signal transduction inhibitors (HER2 inhibitors, BRAF inhibitors, EGFR inhibitors), angiogenesis inhibitors, immunotherapy drugs (such as drugs that target CTLA-4 protein).
2nd Generation GcMAF has the advantage of having no adverse effects so treatment need to be continued as long as essential while disease exists. This is a significant advantage over lots of standard treatments which have cumulative toxicity that limits their usage.
GcMAF never ever quits working and will continue to trigger macrophages while treatment is continued, either by GcMAF injections and/or oral administration of Colostrum GcMAF. (10 ).